Vitamin K2 therapy for myelodysplastic syndromes (MDS) and post-MDS acute myeloid leukemia: information through a questionnaire survey of multi-center pilot studies in Japan

[1] Greenberg PL(1997)International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079-2088

[2] Cox C(1994)Age-related incidence and other epidemiological aspects of myelodysplastic syndrome Br J Haematol 87 743-745

[3] LeMeau MM(1995)Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute leukemia following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of European Organization for Research and Treatment in Cancer (EORTC-LCG) Leukemia 9 1805-1811

[4] Fenaux P(1996)Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes Semin Hematol 33 196-205

[5] Morel P(1997)Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all- Leukemia 11 779-787

[6] Sanz G(1998) retinoic acid Leukemia 12 1392-1397

[7] Sanz M(1994)Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptosis cells using APO2.7 monoclonal antibody Biochem Biophys Res Commun 205 1305-1310

[8] Vallespi T(1999)Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines Int J Hematol 69 24-26

[9] Hamblin T(1999)Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog Leukemia 13 144-145

[10] Oscier D(1998)Vitamin K2 therapy for a patient with myelodysplastic syndrome J Bone Miner Metab 16 106-112

[1] Greenberg PL(1997)International scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079-2088

[2] Cox C(1994)Age-related incidence and other epidemiological aspects of myelodysplastic syndrome Br J Haematol 87 743-745

[3] LeMeau MM(1995)Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute leukemia following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of European Organization for Research and Treatment in Cancer (EORTC-LCG) Leukemia 9 1805-1811

[4] Fenaux P(1996)Intensive chemotherapy and bone marrow transplantation for myelodysplastic syndromes Semin Hematol 33 196-205

[5] Morel P(1997)Vitamin K2 and its derivatives induce apoptosis in leukemia cells and enhance the effect of all- Leukemia 11 779-787

[6] Sanz G(1998) retinoic acid Leukemia 12 1392-1397

[7] Sanz M(1994)Vitamin K2 selectively induces apoptosis of blastic cells in myelodysplastic syndrome: flow cytometric detection of apoptosis cells using APO2.7 monoclonal antibody Biochem Biophys Res Commun 205 1305-1310

[8] Vallespi T(1999)Novel role of vitamin K2: a potent inducer of differentiation of various human myeloid leukemia cell lines Int J Hematol 69 24-26

[9] Hamblin T(1999)Successful therapy of myelodysplastic syndrome with menatetrenone, a vitamin K2 analog Leukemia 13 144-145

[10] Oscier D(1998)Vitamin K2 therapy for a patient with myelodysplastic syndrome J Bone Miner Metab 16 106-112